CD34 and cyclic hematopoiesis: To further evaluate the efficacy of PRECISE editing as a potential treatment for ELANE-CN, we tested it in primary bone marrow-derived CD34+ HSPCs from three ELANE-CN patients, harboring ELANE mutations (NP_001963.1): CN1: p.Trp156Cys, CN2: p.F199LfsX16, and CN3: p.Arg103Pro (Figure S4A).